CAR T-Cell Therapy

Prasad S. Adusumilli, MD, FACS, discusses the current role of chimeric antigen receptor T-cell therapy as treatment of patients with solid tumors and how this is evolving compared to CAR T cells in hematologic malignancies.

Andrea Price, APN, discusses adding CAR T-cell therapy to the electronic medical record.

Early steroid intervention has the potential to reduce the severity of adverse events associated with axicabtagene ciloleucel in patients with refractory large B-cell lymphoma, according to an analysis of the phase I/II ZUMA-1 trial.

Tania Jain, MBBS, discusses hematopoietic recovering following treatment with a chimeric antigen receptor T-cell therapy in patients with hematologic malignancies.

Jeremy S. Abramson, MD, discusses the results of the multicenter phase I TRANSCEND NHL 001 study evaluating the safety and efficacy of lisocabtagene maraleucel in relapsed/refractory large B-cell lymphoma.

The FDA has granted a priority review designation to a biologics license application for the anti-CD19 CAR T-cell therapy lisocabtagene maraleucel for the treatment of adult patients with relapsed/refractory large B-cell lymphoma after at least 2 prior therapies.

Ankit Kansagra, MD, discusses remaining questions with CAR T-cell therapy in multiple myeloma.

Deepu Madduri, MD, discusses the results of the CARTITUDE-1 trial and the next phase of development with JNJ-4528.

Peter Voorhees, MD, discusses the role of CAR T-cell therapy in multiple myeloma.

Ankit Kansagra, MD, discusses the expanding role of CAR T-cell therapy in lymphoma and multiple myeloma.

Praveen Ramakrishnan, MD, spotlights some of the exciting data recently presented across the spectrum of non-Hodgkin lymphoma treatment.

Ankit Kansagra, MD, discusses the evolving use of CAR T-cell therapy in multiple myeloma and lymphoma.

CAR T cells are a highly active field of investigation, with many companies at work on formulations they hope to bring to market, but these agents have limitations, particularly with metastasized solid tumors.